

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review **TA704 and TA862)**

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Company Daiichi-Sankyo (trastuzumab deruxtecan) Patient/carer groups Black Health Agency for Equality Breast Cancer Now Breast Cancer UK Cancer Black Care Cancer Equality Lobular Breast Cancer Make 2nd's Count Macmillan Cancer Support Maggie's Centres Marie Curie MET UP UK Prevent Breast Cancer South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Healthcare professional groups Association of Breast Surgery Association of Cancer Physicians British Geriatrics Society British Institute of Radiology British Psychosocial Oncology 	 Possible comparator companies Accord healthcare (capecitabine, trastuzumab ,vinorelbine) Dr Reddy's laboratories (capecitabine) Eisai (eribulin)

Stakeholder list Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and T A862) ID5121

Issue date: March 2025




Provisional Consultees Provisional Commentators (no right to submit or appeal) Cancer Research UK Glenmark pharmaceuticals Royal College of Anaesthetists (capecitabine) Royal College of General Practitioners Medac GmbH (vinorelbine) Royal College of Nursing Morningside healthcare (capecitabine) Royal College of Pathologists Mylan (capecitabine) Napp pharmaceuticals (trastuzumab) Royal College of Physicians Pierre Fabre (vinorelbine) Royal College of Radiologists Royal College of Surgeons of England Organon Pharma (trastuzumab) Pfizer (trastuzumab) Royal Pharmaceutical Society Roche (trastuzumab emtansine, Royal Society of Medicine capecitabine) Society and College of Radiographers **UK Breast Cancer Group** Relevant research groups **UK Clinical Pharmacy Association Against Breast Cancer UK Health Forum Breast Cancer Research Trust UK Oncology Nursing Society** Cochrane Breast Cancer Group Genomics England **Others** Institute of Cancer Research MRC Clinical Trials Unit Department of Health and Social Care National Cancer Research Institute NHS England National Cancer Research Network National Institute for Health Research Pro-Cancer Research Fund Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Stakeholder list Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and T A862) ID5121

Issue date: March 2025



Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Stakeholder list Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and T A862) ID5121

Issue date: March 2025